Zealand Pharma Shares Plunge: Disappointing Obesity Data Sends Investors Fleeing

It wasn’t a pretty morning for shareholders of Zealand Pharma. On Wednesday, the company released new data for its obesity drug project, and the reaction from investors was brutal. The Zealand Pharma share price took a nosedive, at one point looking like it might lose a third of its value. It’s the kind of day that makes you consider turning off the screen and going for a walk instead.

Why the hammer fell so hard

I’ve spoken to a couple of equity chiefs today, and the picture is pretty clear: The data just wasn’t good enough to justify the hype that had built up. In the biotech game, it’s all about the curves needing to head in the right direction. And here, they were off. The Zealand Pharma share price had been on a massive run-up beforehand, with everyone wanting a piece of the obesity action. But with competition as fierce as it is, especially from Novo Nordisk, investors are quick to head for the exits if the data doesn't match the sky-high expectations. It's brutal, but that's the game.

One of the big Danish investment banks has already sent out an update slashing their price target. It's a classic case: expectations were cranked up so high that even a solid result would have felt like a letdown if it wasn't absolutely game-changing. And here, it was more 'decent' than 'groundbreaking'.

Your quick guide to the Zealand Pharma share right now

So, should you sell in a panic or buy the dip? Let's do a quick, cold, hard zealand pharma share review of the situation:

• What do the data actually say? They showed an effect, but not enough to threaten the established heavyweights. There were side effects, too. It doesn't change the fact that Zealand has a strong pipeline, but it definitely puts the party on hold.
• Is the case dead? No. But it's wounded. The company now needs to prove they can carve out their own niche or improve the data in the next trial round. That takes time.
• Short-term or long-term? If you're a day trader, you've probably moved on. But if you're doing your own zealand pharma share guide with a multi-year time horizon, a drop like this could be an opportunity. It just requires you to have faith in the science and the management.

How to use this share in your portfolio

How to use zealand pharma share sensibly? My personal rule is that biotech stocks like this should make up just a small slice of the pie. The rest should be something boring and stable. Because when the fall comes like it did yesterday, you need to be able to sleep at night without checking the price every five minutes.

My best guess right now is to let the dust settle. See what the company itself says in the coming days, and gauge whether your stomach can handle this kind of rollercoaster ride. Because the Zealand Pharma share price isn't going to be a calm journey. It's going to be a f***ing rollercoaster. But for some, that's exactly what makes it exciting.